The Prognostic Risk Factors of ECMO in Patients with Cardiogenic Shock: A Retrospective Cohort Analysis
Background: Advances in ECMO have rapidly progressed in recent years; however, the clinical mortality rate remains high. This study aimed to identify the risk factors of ECMO in patients with cardiogenic shock.
Methods: Data of patients with cardiogenic shock who received ECMO from January 2006 to August 2013 at the Affiliated Hospital of Sun Yat-Sen University were retrospectively analyzed. All patients with cardiogenic shock were divided into two groups according to whether death occurred in the hospital. The possible prognostic risk factors of ECMO were first obtained in a univariate analysis of the two groups, and the risk factors that affected the prognosis of patients who underwent ECMO were determined using a logistic regression analysis.
Results: This study included 94 cardiogenic shock patients who were treated with ECMO. Overall, 59 patients were successfully weaned from ECMO, which accounted for 62.7% of all patients. The multivariate analysis indicated that the independent risk factors associated with prognosis included ECMO timing (OR = 7.68; 95% CI 1.60-37.01), the occurrence of postoperative MOF (OR = 2,823.09; 95% CI 14.75-540,171.06), and the lactate level at weaning (OR = 493.17; 95% CI: 1.55-156,653.27).
Conclusion: For patients with refractory cardiogenic shock, the early establishment of ECMO, improvement in perfusion, and the prevention of complications may improve the prognosis.
Bakhtiary F, Keller H, Dogan S, et al. 2008. Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock: clinical experiences in 45 adult patients. J Thorac Cardiovasc Surg 135:382-8.
Bermudez CA, Rocha RV, Toyoda Y, et al. 2011. Extracorporeal membrane oxygenation for advanced refractory shock in acute and chronic cardiomyopathy. Ann Thorac Surg 92: 2125-31.
Bhat P, Hirsch JC, Gelehrter S, et al. 2013. Outcomes of infants weighing three kilograms or less requiring extracorporeal membrane oxygenation after cardiac surgery. Ann Thorac Surg 95:656-61.
Bittner HB, Binner C, Lehmann S, et al. 2007. Replacing cardiopulmonary bypass with extracorporeal membrane oxygenation in lung transplantation operations. Eur J Cardiothorac Surg 31:462-7; discussion 467.
Chaturvedi RR, Macrae D, Brown KL, et al. 2004. Cardiac ECMO for biventricular hearts after paediatric open heart surgery. Heart 90:545-51.
Cottini SR, Wenger U, Sailer S, et al. 2013. Extracorporeal membrane oxygenation: beneficial strategy for lung transplant recipients. J Extra Corpor Technol 45:16-20.
Davies A, Jones D, Bailey M, et al. 2009. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. Australia, New Zealand Extracorporeal Membrane Oxygenation Influenza I. JAMA 302:1888-95.
Delius RE, Bove EL, Meliones JN, et al. 1992. Use of extracorporeal life support in patients with congenital heart disease. Crit Care Med 20:1216-22.
Fayssoil A, Nardi O, Orlikowski D, Combes A, Chastre J, Annane D. 2010. Percutaneous extracorporeal membrane oxygenation for cardiogenic shock due to acute fulminant myocarditis. Ann Thorac Surg 89:614-16.
Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. 2004. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90:297-303.
Hill JD, O’Brien TG, Murray JJ, et al. 1972. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. N Engl J Med 286:629-34.
Hsu PS, Chen JL, Hong GJ, et al. 2010. Extracorporeal membrane oxygenation for refractory cardiogenic shock after cardiac surgery: predictors of early mortality and outcome from 51 adult patients. Eur J Cardiothorac Surg 37:328-33.
Kane DA, Thiagarajan RR, Wypij D, et al. 2010. Rapid-response extracorporeal membrane oxygenation to support cardiopulmonary resuscitation in children with cardiac disease. Circulation 122:S241-8.
Kim H, Lim SH, Hong J, et al. 2012. Efficacy of veno-arterial extracorporeal membrane oxygenation in acute myocardial infarction with cardiogenic shock. Resuscitation 83: 971-5.
Ko WJ, Chen YS, Chou NK, Wang SS, Chu SH. 1997. Extracorporeal membrane oxygenation in the perioperative period of heart transplantation. J Formos Med Assoc 96: 83-90.
Ko WJ, Lin CY, Chen RJ, Wang SS, Lin FY, Chen YS. 2002. Extracorporeal membrane oxygenation support for adult postcardiotomy cardiogenic shock. Ann Thorac Surg 73: 538-45.
Kumar TK, Zurakowski D, Dalton H, et al. 2010. Extracorporeal membrane oxygenation in postcardiotomy patients: factors influencing outcome. J Thorac Cardiovasc Surg 140: 330-6.e332.
Langley SM, Sheppard SV, Tsang VT, Monro JL, Lamb RK. 1998. When is extracorporeal life support worthwhile following repair of congenital heart disease in children? Eur J Cardiothorac Surg 13:520-5.
Maisel AS, Krishnaswamy P, Nowak RM, et al. 2002. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-7.
Noah MA, Peek GJ, Finney SJ, et al. 2011. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 306:1659-68.
Paden ML, Warshaw BL, Heard ML, Fortenberry JD. 2011. Recovery of renal function and survival after continuous renal replacement therapy during extracorporeal membrane oxygenation. Pediatr Crit Care Med 12:153-8.
Paden ML, Conrad SA, Rycus PT, Thiagarajan RR, Registry E. 2013. Extracorporeal Life Support Organization Registry Report 2012. ASAIO J 59:202-10.
Patroniti N, Zangrillo A, Pappalardo F, et al. 2011. The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks. Intensive Care Med 37:1447-57.
Peek GJ, Mugford M, Tiruvoipati R, et al. 2009. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 374: 1351-63.
Rastan AJ, Dege A, Mohr M, et al. 2010. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg 139:302-11.e301.
Slottosch I, Liakopoulos O, Kuhn E, et al. 2013. Outcomes after peripheral extracorporeal membrane oxygenation therapy for postcardiotomy cardiogenic shock: a single-center experience. J Surg Research 181:e47-55.
Smith A, Hardison D, Bridges B, Pietsch J. 2013. Red blood cell transfusion volume and mortality among patients receiving extracorporeal membrane oxygenation. Perfusion 28:54-60.
Tsao NW, Shih CM, Yeh JS, et al. 2012. Extracorporeal membrane oxygenation-assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock. J Crit Care 27:530 e531-511.
Wu MY, Lin PJ, Tsai FC, Haung YK, Liu KS, Tsai FC. 2008. Impact of preexisting organ dysfunction on extracorporeal life support for non-postcardiotomy cardiopulmonary failure. Resuscitation 79:54-60.
Yuan Y, Dong JT, Huang XS, et al. 2006. Successful extracorporeal membrane oxygenation support in a patient with fulminant myocarditis. Chin Med Sci J 21:194-6.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).